CMO Moves: Regulatory catalysts for drug manufacturing – March 2023
The biotech industry is currently undergoing a wider financial upheaval after the collapse of Silicon Valley Bank (SVB), which was…
All articles by Fiona Barry
Fiona Barry
Fiona Barry is the Editor-in-Chief of GlobalData PharmSource’s editorial content. She previously worked as an investigative journalist reporting scoops on drug trials, contract pharma, rare diseases, and women’s health.
-
-
CMO Moves: Regulatory catalysts for drug manufacturing- February
Manufacturing a drug therapy usually involves several different stakeholders. Contract manufacturing organizations (CMOs) not only produce the active pharmaceutical ingredient…
-
Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict
The EU is planning a sweeping revision of its pharma legislation in March, the largest change in 20 years. The…
-
CMO Moves: Regulatory catalysts for therapy manufacturing -January
In the first 2023 edition of the CMO Moves monthly series, Pharmaceutical Technology explores recent news stories on regulatory and…
-
CMO Moves: Regulatory catalysts for drug manufacturing-December
In this last 2022 edition of the series, which started in June, Pharmaceutical Technology is tracking major trial announcements and…
-
CMO Moves: Regulatory catalysts for drug manufacturing-November
Crossing the approval hurdle for a new drug is a big milestone for pharmaceutical companies. However, efficiently manufacturing the drug…
-
CMO Moves: Regulatory catalysts for drug manufacturing-October
As the pharmaceutical industry, along with the rest of the corporate sector, enters the last quarter of the year, all…
-
CMO Moves: Regulatory catalysts for drug manufacturing-September
In recent weeks, several regulatory decisions on Covid-19 vaccines and boosters have come through that are expected to spur vaccine…
-
CMO Moves: Regulatory catalysts for drug manufacturing—August
Pharmaceutical and biotech companies live and die by regulatory decisions on their therapies. These verdicts not only impact the company…
-
California’s low-cost insulin plans receive $100m manufacturing boost
Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to…